title: Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
abstract: A two-dose vaccination programme using a combined measles, mumps and rubella vaccine (MMR) and administration at the ages of 18 months and 12 years was introduced in 1982. The 12-year-old schoolchildren were tested yearly from 1985 to 1989 on serum samples obtained prior to and after vaccination. Each year between 420 and 756 children were tested. The method used for antibody testing was the haemolysis-in-gel (HIG) assay. For measles also the enzyme-linked immunosorbent assay (ELISA) and the neutralization titre (NT) were applied. Only minor variations of the prevaccination immunity to measles were seen during the period 3-7 years after introduction of the programme. The age groups studied had partly been vaccinated against measles earlier. Between 12 and 16% lacked prevaccination immunity. In contrast the immunity to mumps and rubella of the 12-year-old children decreased considerably during the study period. No general vaccination against these diseases had been performed. Thus the susceptibility to mumps increased from 14% in 1985 to 39% in 1989 and to rubella from 41 to 57%. The seroconversion rate of children seronegative for measles was high, i.e. 100% in 1985 and later varied between 96 and 97%. For mumps, the seroconversion rate was lower and varied between 72 and 88%. All sera converted to rubella. During the follow-up period there was a declining incidence of measles, mumps and rubella. The relationship between the vaccination and reduction of disease and natural immunity strongly suggests that the association is causal and that this vaccination policy reduced the transmission of infection.
authors.affiliation: Department of Epidemiology, National Bacteriological Laboratory, Stockholm, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Christenson
authors.forename: M
authors.initials: M
authors.lastname: Böttiger
mesh_terms: D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D004338:Drug Combinations; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000008:administration & dosage* / Q000276:immunology; D009109:Mumps virus / Q000276:immunology; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000276:immunology; D012412:Rubella virus / Q000276:immunology; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine